期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗联合化疗治疗霍奇金淋巴瘤一例并文献复习

原文传递
导出
摘要 目的分析利妥昔单抗联合化疗方案治疗霍奇金淋巴瘤（HL）的疗效。方法采用利妥昔单抗联合ABVD方案治疗1例经典型HL（cHL）并复习文献。结果HL组织中有CD20＋表达，结节性淋巴细胞为主型表达率98％～100％，经典型表达率18％-32％。RS干细胞中亦有CD20＋刍表达．利妥昔单抗针对CD高细胞，清除RS细胞，抑制RS于细胞及反应性背景B细胞，阻断肿瘤细胞存活信号。利妥昔单抗单药治疗的临床反应率在结节性淋巴细胞为主型83％～100％，经典型22％；与化疗联合应用，明显延长病情缓解期，提高治疗反应率。临床Ⅱ期观察利妥昔单抗联合ABVD方案治疗cHL患者，完全缓解率达81％-93％，5年无瘤生存率及总体生存率分别为83％和96％。泼例患者治疗获得缓解，随访1年，健康生存。结论利妥昔单抗联合化疗治疗HL安全有效。
作者 罗社文 王希 毛积分 赵凤翎 宋晓萍 李昕权
机构地区 武警总医院国际医疗中心 武警总医院血液科 北京中日友好医院高干科
出处 《白血病．淋巴瘤》 CAS 2012年第12期751-753,共3页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 霍奇金 抗肿瘤联合化疗方案
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1李义,克晓燕.进展期霍奇金淋巴瘤的理想治疗方案[J].白血病．淋巴瘤,2012,21(2):68-69. 被引量：1
  • 2Saini KS, Azim HA, Cocorocehio E, et al. Rituxirnab in Hodgkin lymphoma: is the target always a hit. Cancer Treat Rev, 2011, 37: 385- 390.
  • 3Sjoberg J, Hahhur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood, 2012, 119: 990-996.
  • 4Nogova L, Ileineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphnma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol, 2008, 26: 434-439.
  • 5Hedvat CV, Hegde A, Chaganti RS, et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol, 2002, 33: 968-974.
  • 6Boudova L, Tor|akovic E, Delabie J, et al. Nodular lymphocyte- predominant Hodgkin lymphoma with nodules resembling T- eetl]histiocyte-rieh B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T- eell/histioeyte-rieh B-cell lymphoma. Blood, 2003, 102: 3753-3758.
  • 7Rassidakis GZ, Medeiros L J, Viviani S, et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting featnres and clinical outcome. J Clin Oncol, 2002, 20: 1278-1287.
  • 8Fromm JR, Thomas A, Wood BL. Flow cytometiy can diagrmse classical Hodgkin lymphoma in lymph nodes with high sensitivity and specificity. Am J Clin Pathol, 2009, 131 : 322-332.
  • 9Jones R J, Gocke CD, Kasamon YL, et al. Circulating clonotypic B ceils in classic Hodgkin lymphoma. Blood, 2009, 113: 5920-5926.
  • 10Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: longterm results of a phase 2 trim by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 2008, 111:109-111.

二级参考文献34

  • 1Macdonald DA,Ding K,Gospodarowicz MK,et al.Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.Ann Oncol,2007,18:1680-1684.
  • 2Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma:National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.J Clin Oncol,2005,23:4634-4642.
  • 3Radford J, O'Doherty M, Barrington S, et al. Results of the 3rd planned interim analysis of the UK NCRI rapid trial (involved field radiotherapy versus no further treatment)in patients with clinical stages Ⅰ A/Ⅱ A Hodgkin lymphoma and a 'negative' 18FDG-PET scan after 3 cycles ABVD[Abstract].Haematologica,2010,95 (suppl 4):S16.
  • 4Gallamini A,Hutchings M,Rigacci L,et al.Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advancedstage Hodgkin's lymphoma:a report from a joint Italian-Danish study.J Clin Oncol,2007,25:3746-3752.
  • 5Hutchings M,Mikhaeel NG,Fields PA,et al.Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.Ann Oncol,2005,16:1160-1168.
  • 6Horning SJ,Juweid ME,Schoder H,et al.Interim positron emission tomography scans in diffuse large B-cell lymphoma:an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.Blood,2010,115:775-777.
  • 7Abramson JS,Barnes JA,LaCasce AS,et al.End of treatment but not interim PET scan predicts outcome in non-bulky limited stage Hodgkin lymphoma[Abstract].Haematologica,2010,95 (suppl 4):S16.
  • 8Terasawa T,Lau J,Bardet S,et al.Fluorine-18-fluorodeoxyglu-cose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma:a systematic review.J Clin Oncol,2009,27:1906-1914.
  • 9Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma.N Engl J Med,2003,348:2396-2406.
  • 10EngertA, KobeC, MarkovaJ, etal. Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy:Final report of the GHSG HD15 trial[Abstract].Blood,2010,116:764.

共引文献1

白血病．淋巴瘤
2012年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部